February 22, 2021 -- Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.
The two pharmas are developing an adjuvanted recombinant protein vaccine. Their phase II study, which will enroll 720 adult volunteers, will evaluate three different antigen doses to determine the best strategy for phase III development. If successful, the partners plan to move the candidate into phase III in the second quarter.